<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01151319</url>
  </required_header>
  <id_info>
    <org_study_id>HIV-CORE 002</org_study_id>
    <nct_id>NCT01151319</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity Study of Three Candidate HIV-1 Vaccines, Administered in Combination to Healthy HIV-1 Uninfected Adults</brief_title>
  <acronym>HIV-CORE 002</acronym>
  <official_title>A Randomized Single-blind Placebo-controlled Study to Evaluate the Safety and Immunogenicity of Three Candidate HIV-1 Vaccines, pSG2.HIVconsv DNA, ChAdV63.HIVconsv and MVA.HIVconsv, Administered in Combination to Healthy HIV 1 Uninfected Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Oxford</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomised, placebo-controlled, single-blind study designed to evaluate the safety&#xD;
      and immunogenicity of three novel HIV vaccines.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>Actively collected data throughout the study until 6 months after the last vaccination</time_frame>
    <description>Proportion of volunteers who develop a grade 3 or 4 local reaction.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>Samples will be collected at every visit pre- and post vaccination</time_frame>
    <description>Proportion of volunteers who develop new CD8+ and CD4+ T cell responses to one or more HIV-1 epitopes, as determined by IFN-γ ELISPOT assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>Stage 1; screen, 0, 1, 2, 4, 8, 16, 28 wk. Stage 2; screen, 0, 1, 2, 4, 8, 9, 12, 20, 28 wk. Stage 3; screen, 1, 8, 12, 13, 14, 20, 21, 22, 28 wk. Stage 4; screen, 0, 8, 12, 13, 16, 17, 18, 24, 28 wk post vac. Stage 2 &amp; 3: 6,12,24 mth after last vaccine</time_frame>
    <description>Exploration of the efficacy of vaccine-induced CD8+ T cells to suppress HIV-1 replication in vitro.</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>HIV-1 Infections</condition>
  <arm_group>
    <arm_group_label>Stage 1.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The first stage will start from a low and well tolerated, but likely less immunogenic dose of ChAdV63.HIVconsv (n=2).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The highest dose of ChAdV63.HIVconsv followed by boost with MVA.HIVconsv at week 0 and 8, respectively (n=8). Followed up at 6,12 and 24 months after last vaccination.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three doses of pSG2.HIVconsv DNA followed by boost with high dose ChAdV63.HIVconsv followed by boost with MVA.HIVconsv at week 0,4,8,12 and 20, respectively (n=8). Followed up at 6, 12 and 24 months after last vaccination.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three doses of pSG2.HIVconsv DNA followed by boost with MVA.HIVconsv followed by boost with high dose ChAdV63.HIVconsv at weeks at week 0,4,8,12 and 16, respectively (n=8).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 2 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Time-course matched to vaccinations (n=2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 3 placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Time-course matched to vaccinations (n=2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 4 placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Time-course matched to vaccinations (n=2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ChAdV63.HIVconsv low dose.</intervention_name>
    <description>Attenuated chimp adenovirus. 5x10^9 virus particles.</description>
    <arm_group_label>Stage 1.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ChAdV63.HIVconsv high dose.</intervention_name>
    <description>Attenuated chimp adenovirus at 5x10^10 virus particles.</description>
    <arm_group_label>Stage 2</arm_group_label>
    <arm_group_label>Stage 3</arm_group_label>
    <arm_group_label>Stage 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pSG2.HIVconsv</intervention_name>
    <description>DNA at 4mg per dose.</description>
    <arm_group_label>Stage 3</arm_group_label>
    <arm_group_label>Stage 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MVA.HIVconsv</intervention_name>
    <description>Attenuated poxvirus at 4x10^8 plaque forming units per dose.</description>
    <arm_group_label>Stage 2</arm_group_label>
    <arm_group_label>Stage 3</arm_group_label>
    <arm_group_label>Stage 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Phosphate buffered saline</description>
    <arm_group_label>Stage 2 Placebo</arm_group_label>
    <arm_group_label>Stage 3 placebo</arm_group_label>
    <arm_group_label>Stage 4 placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy males or females, as assessed by a medical history, physical examination and&#xD;
             laboratory tests.&#xD;
&#xD;
          2. Aged at least 18 years on the day of screening and no greater than 50 years on the day&#xD;
             of the first vaccination.&#xD;
&#xD;
          3. Willing to comply with the requirements of the protocol and available for follow-up&#xD;
             for the planned duration of the study.&#xD;
&#xD;
          4. In the opinion of the principal investigator or designee, the volunteer has understood&#xD;
             the information provided. Written informed consent must be given before any&#xD;
             study-related procedures are performed.&#xD;
&#xD;
          5. Willing to undergo HIV-1 testing, HIV-1 counselling and receive HIV-1 test results.&#xD;
&#xD;
          6. If heterosexually active female; using an effective method of contraception (e.g.&#xD;
             hormonal contraception, diaphragm, intra-uterine device (IUD), condoms, anatomical&#xD;
             sterility in self or partner) from 14 days prior to the first vaccination until at&#xD;
             least 6 weeks after the last vaccination; all female volunteers must be willing to&#xD;
             undergo urine pregnancy tests at time points specified in the protocol.&#xD;
&#xD;
          7. If heterosexually active male; willing to use an effective method of contraception&#xD;
             (condoms; anatomical sterility in self or partner) from the day of the first&#xD;
             vaccination until 6 weeks after the last vaccination.&#xD;
&#xD;
          8. Willing to forgo donations of blood during the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any clinically significant acute or chronic medical condition that is considered&#xD;
             progressive or, in the opinion of the principal investigator or designee, would make&#xD;
             the volunteer unsuitable for the study.&#xD;
&#xD;
          2. Any of the following abnormal laboratory parameters listed below:&#xD;
&#xD;
             Haematology&#xD;
&#xD;
               -  Haemoglobin &lt; 10.0 g/dl&#xD;
&#xD;
               -  Absolute Neutrophil Count (ANC) ≤ 1000 /mm3 (≤ 1 x 109 /l)&#xD;
&#xD;
               -  Absolute Lymphocyte Count (ALC) ≤ 600 /mm3 (≤ 1 x 109 /l)&#xD;
&#xD;
               -  Platelets ≤100,000 /mm3, ≥ 550,000 /mm3 (≤ 90 /l, ≥ 550 /l) Biochemistry&#xD;
&#xD;
               -  Creatinine &gt; 1.3 x ULN&#xD;
&#xD;
               -  Aspartate aminotransferase (AST) &gt; 2.5 x ULN&#xD;
&#xD;
               -  Alanine aminotransferase (ALT) &gt; 2.5 x ULN Urinalysis&#xD;
&#xD;
               -  Abnormal dipstick confirmed by microscopy&#xD;
&#xD;
          3. Reported high-risk behaviour for HIV infection. High-risk behaviour for HIV-1&#xD;
             infection is defined as follows. Within the previous 6 months the volunteer has:&#xD;
&#xD;
               -  Had unprotected vaginal or anal sex with a known HIV-infected person or a casual&#xD;
                  partner (i.e., no continuing, established relationship)&#xD;
&#xD;
               -  Engaged in sex work for money or drugs&#xD;
&#xD;
               -  Used injection drugs&#xD;
&#xD;
               -  Acquired one of the following sexually transmitted disease (STD); Chlamydia,&#xD;
                  gonorrhoea and syphilis.&#xD;
&#xD;
          4. Confirmed HIV-1 or HIV-2 infection.&#xD;
&#xD;
          5. If female, pregnant or planning a pregnancy within 6 weeks after last vaccination; or&#xD;
             lactating.&#xD;
&#xD;
          6. Receipt of live attenuated vaccine within the previous 60 days (live attenuated flu&#xD;
             vaccine within 14 days) or planned receipt within 60 days after vaccination with&#xD;
             Investigational Product or receipt of other vaccine within the previous 14 days or&#xD;
             planned receipt within14 days after vaccination with Investigational Product.&#xD;
&#xD;
          7. Receipt of blood transfusion or blood products within the previous 6 months.&#xD;
&#xD;
          8. Participation in another clinical trial of an Investigational Product currently,&#xD;
             within the previous 3 months or expected participation during this study.&#xD;
&#xD;
          9. Receipt of any investigational HIV vaccine within the last 6 years.&#xD;
&#xD;
         10. History of severe or very severe local or systemic reactogenicity events, or history&#xD;
             of severe or very severe allergic reactions.&#xD;
&#xD;
         11. Confirmed diagnosis of hepatitis B virus (surface antigen, HBsAg), hepatitis C virus&#xD;
             (HCV antibodies) or active syphilis.&#xD;
&#xD;
         12. Smallpox vaccination within the previous 3 years (smallpox vaccination prior to 3&#xD;
             years should be documented but is not an exclusion criterion).&#xD;
&#xD;
         13. Major psychiatric illness including any history of schizophrenia or severe psychosis,&#xD;
             bipolar disorder requiring therapy, suicidal attempt or ideation in the previous 3&#xD;
             years.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tomas Hanke</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oxford</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lucy Dorrell</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oxford</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre for Clinical Vaccinology and Tropical Medicine</name>
      <address>
        <city>Oxford</city>
        <state>Oxon</state>
        <zip>OX3 9DZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <study_first_submitted>June 24, 2010</study_first_submitted>
  <study_first_submitted_qc>June 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2010</study_first_posted>
  <last_update_submitted>April 29, 2014</last_update_submitted>
  <last_update_submitted_qc>April 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

